Exelixis is giving up on its tissue factor (TF)-targeting antibody ... The biotech had been evaluating the ADC, dubbed XB002, in the phase 1 JEWEL-101 trial in advanced solid tumors and said ...

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two ...

Dr. Lone Ottesen, Chief Medical Officer of Adcendo, said: "uPARAP is a highly attractive target for the development of an ADC in mesenchymal cancers including soft tissue sarcoma, as it is highly ...